GSK Says Depemokimab For Chronic Rhinosinusitis Reduces Nasal Polyp Size, Nasal Obstruction Versus Placebo At One Year
AstraZeneca's Lung Cancer Drug Enhertu Gets Conditional Approval in China
Daiichi Sankyo/astrazeneca (AZN.US)'s 'Tecentriq' has been approved in China.
On October 14th, the official website of the China National Medical Products Administration disclosed that the new indication for lung cancer of the injection-type trastuzumab deruxtecan (Enhertu) declared by Daiichi Sankyo has obtained marketing approval. Trastuzumab deruxtecan is a HER2-targeted antibody-drug conjugate jointly developed by Astrazeneca (AZN.US) and Daiichi Sankyo.
AstraZeneca Expanding R&D Pipeline in China
GSK Settles Majority Of Zantac Lawsuits, But Pipeline Doubts Remain
Express News | AstraZeneca PLC Reports 9.9% Passive Stake in Conduit Pharmaceuticals Inc as of August 7 - SEC Filing
![Chinese Stocks Surge on Return from Holidays as Euphoria Extends [CSOP Global Market Morning Report]](https://ussnsimg.moomoo.com/sns_client_feed/71451441/20241008/1728367312428-c514003b5c.jpeg/thumb?area=999&is_public=true)
